Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in MelanomaOmid Hamid, Antoni Ribas, Scot Ebbinghaus et al.|New England Journal of Medicine|2013Cited by 3.4k
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trialCaroline Robert, Adil Daud, Antoni Ribas et al.|The Lancet|2014Cited by 1.8k
Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced MelanomaAntoni Ribas, Caroline Robert, Omid Hamid et al.|JAMA|2016Cited by 1.1k
Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL).Antoni Ribas, Caroline Robert, F. Stephen Hodi et al.|Journal of Clinical Oncology|2014Cited by 130
Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL).Antoni Ribas, Caroline Robert, F. Stephen Hodi et al.|Journal of Clinical Oncology|2014Cited by 54